Transaction #3313 · Form 4 · 0001493152-25-020222
Cocrystal Pharma, Inc. · Stock award · Common Stock
Cocrystal Pharma, Inc. · Transacted October 28, 2025 · Filed October 30, 2025
What does this filing report?
An SEC Form 4 filing for Cocrystal Pharma, Inc. records a stock award involving Common Stock on October 28, 2025. The reported quantity was 359,713. The filing date is October 30, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Cocrystal Pharma, Inc.
- Company CIK
- 0001412486
- Security type
- Non-derivative
- Acquisition type
- Stock award · Code A
- Quantity acquired
- 359,713
- Reported price
- 1.39
- Reference value
- 500,001.07
- Currency
- Currency not specified
- Ownership
- Indirect
- Holdings after transaction
- 1,679,551
- Ownership description
- By Frost Gamma Investments Trust
- SEC acceptance time
- Oct 30, 2025, 4:15 PM EDT
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- FROST PHILLIP MD ET AL ↗
Director · 10% owner
CIK 0000898860
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- The Reporting Person purchased units at $1.39 per unit with each unit consisting of one share of common stock and a warrant to purchase two shares of common stock. The shares of common stock and warrants purchased are exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by a Special Committee of the Board of Directors of the Issuer, which Special Committee consisted of two non-employee directors. The warrants were exercisable upon issuance.
- F2
- These shares are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole stockholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is the sole stockholder of Frost-Nevada Corporation. The Reporting Person disclaims beneficial ownership of the securities held by Frost Gamma Investments Trust except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
- F3
- Includes shares of common stock issuable upon vesting of restricted stock units.
Remarks
This Form 4 does not include any of the securities owned directly by OPKO Health, Inc., a company of which Dr. Frost is the Chairman of the Board and Chief Executive Officer, concerning the securities of which Dr. Frost does not hold voting and investment control. Dr. Frost disclaims beneficial ownership of the securities held by OPKO Health, Inc. except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that Dr. Frost is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.